Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
New England Journal of Medicine · 15.05.2025 · 392 (19) · 1883-1892
DOI: 10.1056/nejmoa2415988 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 15.05.2025. Verfasst von Robert J Fox und 12 weiteren Autor:innen. Beteiligte Einrichtung: Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland. Hauptthemen laut MEDLINE: Agammaglobulinaemia Tyrosine Kinase, Multiple Sclerosis, Chronic Progressive, Protein Kinase Inhibitors, Tyrosine Kinase Inhibitors. Die Arbeit wurde bisher 158-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Sanofi.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland.
- Center for Neuroinflammation and Experimental Therapeutics, Department of Neurology, University of Pennsylvania, Philadelphia.
- Division of Neurology, University of British Columbia, Vancouver, Canada.
- Department of Neurology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid.
- Departamento de Medicina, Facultad de Medicina, Universidad Complutense de Madrid, Madrid.
- Queen Mary University of London, Blizard Institute, Faculty of Medicine and Dentistry, London.
ORCID-Profile: Robert J Fox, Daniel S Reich
Förderung
- Sanofi
Zitieren
APA
Fox, R. J., Bar-Or, A., Traboulsee, A., Oreja-Guevara, C., Giovannoni, G., Vermersch, P., Syed, S., Li, Y., Vargas, W. S., Turner, T. J., Wallstroem, E., Reich, D. S., & HERCULES Trial Group (2025). Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis. New England Journal of Medicine, 392(19), 1883-1892. https://doi.org/10.1056/nejmoa2415988
Vancouver
Fox RJ, Bar-Or A, Traboulsee A, Oreja-Guevara C, Giovannoni G, Vermersch P, et al. Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis. New England Journal of Medicine. 2025;392(19):1883-1892. doi:10.1056/nejmoa2415988
BibTeX
@article{Fox2025,
author = {Fox, Robert J and Bar-Or, Amit and Traboulsee, Anthony and Oreja-Guevara, Celia and Giovannoni, Gavin and Vermersch, Patrick and Syed, Sana and Li, Ye and Vargas, Wendy S and Turner, Timothy J and Wallstroem, Erik and Reich, Daniel S and HERCULES Trial Group, HERCULES Trial Group},
title = {Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis},
journal = {New England Journal of Medicine},
year = {2025},
volume = {392},
number = {19},
pages = {1883--1892},
doi = {10.1056/nejmoa2415988}
}
EUVIMED